96 related articles for article (PubMed ID: 32676810)
1. Structure-based discovery of small molecule APC-Asef interaction inhibitors: In silico approaches and molecular dynamics simulations.
Jadav SS; Macalino SJY; Alluri R
J Mol Model; 2020 Jul; 26(8):207. PubMed ID: 32676810
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration.
Jiang H; Deng R; Yang X; Shang J; Lu S; Zhao Y; Song K; Liu X; Zhang Q; Chen Y; Chinn YE; Wu G; Li J; Chen G; Yu J; Zhang J
Nat Chem Biol; 2017 Sep; 13(9):994-1001. PubMed ID: 28759015
[TBL] [Abstract][Full Text] [Related]
3. Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy.
Yang X; Zhong J; Zhang Q; Feng L; Zheng Z; Zhang J; Lu S
Front Mol Biosci; 2021; 8():662579. PubMed ID: 33968990
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of 2-H pyrazole derivatives containing morpholine moieties as highly potent small molecule inhibitors of APC-Asef interaction.
Yan XQ; Wang ZC; Qi PF; Li G; Zhu HL
Eur J Med Chem; 2019 Sep; 177():425-447. PubMed ID: 31158755
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the recognition of Asef by adenomatous polyposis coli.
Zhang Z; Chen L; Gao L; Lin K; Zhu L; Lu Y; Shi X; Gao Y; Zhou J; Xu P; Zhang J; Wu G
Cell Res; 2012 Feb; 22(2):372-86. PubMed ID: 21788986
[TBL] [Abstract][Full Text] [Related]
6. Truncated Adenomatous Polyposis Coli Mutation Induces Asef-Activated Golgi Fragmentation.
Kim SB; Zhang L; Yoon J; Lee J; Min J; Li W; Grishin NV; Moon YA; Wright WE; Shay JW
Mol Cell Biol; 2018 Sep; 38(17):. PubMed ID: 29866653
[TBL] [Abstract][Full Text] [Related]
7. Conformational Selection Mechanism Provides Structural Insights into the Optimization of APC-Asef Inhibitors.
He X; Huang N; Qiu Y; Zhang J; Liu Y; Yin XL; Lu S
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670371
[TBL] [Abstract][Full Text] [Related]
8. Rational Design and Structure Validation of a Novel Peptide Inhibitor of the Adenomatous-Polyposis-Coli (APC)-Rho-Guanine-Nucleotide-Exchange-Factor-4 (Asef) Interaction.
Yang X; Zhong J; Zhang Q; Qian J; Song K; Ruan C; Xu J; Ding K; Zhang J
J Med Chem; 2018 Sep; 61(17):8017-8028. PubMed ID: 30095910
[TBL] [Abstract][Full Text] [Related]
9. Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase.
Kawasaki Y; Tsuji S; Sagara M; Echizen K; Shibata Y; Akiyama T
J Biol Chem; 2009 Aug; 284(33):22436-22443. PubMed ID: 19525225
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42.
Kawasaki Y; Sagara M; Shibata Y; Shirouzu M; Yokoyama S; Akiyama T
Oncogene; 2007 Dec; 26(55):7620-267. PubMed ID: 17599059
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel pyrazoline derivatives containing methyl-1H-indole moiety as potential inhibitors for blocking APC-Asef interactions.
Qi PF; Fang L; Li H; Li SK; Yang YS; Qi JL; Xu C; Zhu HL
Bioorg Chem; 2020 Jun; 99():103838. PubMed ID: 32334194
[TBL] [Abstract][Full Text] [Related]
12. Asef, a link between the tumor suppressor APC and G-protein signaling.
Kawasaki Y; Senda T; Ishidate T; Koyama R; Morishita T; Iwayama Y; Higuchi O; Akiyama T
Science; 2000 Aug; 289(5482):1194-7. PubMed ID: 10947987
[TBL] [Abstract][Full Text] [Related]
13. Rational design of a sensitivity-enhanced tracer for discovering efficient APC-Asef inhibitors.
Zhong J; Guo Y; Lu S; Song K; Wang Y; Feng L; Zheng Z; Zhang Q; Wei J; Sang P; Shi Y; Cai J; Chen G; Liu CY; Yang X; Zhang J
Nat Commun; 2022 Aug; 13(1):4961. PubMed ID: 36002443
[TBL] [Abstract][Full Text] [Related]
14. Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression.
Mitin N; Betts L; Yohe ME; Der CJ; Sondek J; Rossman KL
Nat Struct Mol Biol; 2007 Sep; 14(9):814-23. PubMed ID: 17704816
[TBL] [Abstract][Full Text] [Related]
15. Mutated APC and Asef are involved in the migration of colorectal tumour cells.
Kawasaki Y; Sato R; Akiyama T
Nat Cell Biol; 2003 Mar; 5(3):211-5. PubMed ID: 12598901
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
17. Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migration.
Sagara M; Kawasaki Y; Iemura SI; Natsume T; Takai Y; Akiyama T
Oncogene; 2009 Mar; 28(10):1357-65. PubMed ID: 19151759
[TBL] [Abstract][Full Text] [Related]
18. An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity.
El Turk F; Fauvet B; Ouertatani-Sakouhi H; Lugari A; Betzi S; Roche P; Morelli X; Lashuel HA
Bioorg Med Chem; 2010 Jul; 18(14):5425-40. PubMed ID: 20639113
[TBL] [Abstract][Full Text] [Related]
19. Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Kumar R; Parameswaran S; Bavi R; Baek A; Son M; Rampogu S; Park C; Lee G; Zeb A; Parate S; Rana RM; Lee KW
J Mol Graph Model; 2019 May; 88():92-103. PubMed ID: 30665156
[TBL] [Abstract][Full Text] [Related]
20. PH domain-mediated membrane targeting of Asef.
Muroya K; Kawasaki Y; Hayashi T; Ohwada S; Akiyama T
Biochem Biophys Res Commun; 2007 Mar; 355(1):85-8. PubMed ID: 17292853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
